Radiomics of magnetic resonance imaging for assessment of pathological complete response to neoadjuvant therapy and long-term survival in breast cancer

Breast cancer (BC) is the most common malignant disease. The use of neoadjuvant drug therapy increases the likelihood of achieving a complete pathomorphological response (pCR), leads to an increase in resectability and ablation; helps to determine the sensitivity of tumor cells to chemopreventive agents, thereby improving the patient’s prognosis. Since pathomorphological assessment occurs aſter surgery, it is necessary to develop methods for non-invasive response assessment for timely correction of the volume of treatment. One such method is magnetic resonance imaging (MRI). Assessment of the obtained images using texture analysis allows to increase the accuracy of the method both in the control of neoadjuvant treatment and in the assessment of the response to neoadjuvant therapy during preoperative planning.

This article provides an analysis of the literature data on the potential to improve the prognostic value of breast MRI in assessing the complete pathomorphological response to neoadjuvant drug treatment of breast cancer using texture analysis of data.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. https://doi.org/10.3322/caac.21660

2. Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: Tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 2018 Oct 9;10:4333–4347. https://doi.org/10.2147/cmar.s174435

3. Puglisi F, Follador A, Minisini AM, Cardellino GG, Russo S, Andreetta C, Di Terlizzi S, Piga A. Baseline staging tests aſter a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005 Feb;16(2):263–266. https://doi.org/10.1093/annonc/mdi063

4. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147. Epub 2008 Feb 4. Corrected and republished in: J Clin Oncol. 2023 Apr 1;41(10):1809-1815.

5. Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clin Cancer Res. 2016 May 15;22(10):2323–2328. https://doi.org/10.1158/1078-0432.ccr-15-1961

6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27–39. https://doi.org/10.1016/s1470-2045(17)30777-5

7. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-172. https://doi.org/10.1016/s0140-6736(13)62422-8. Erratum in: Lancet. 2019 Mar 9;393(10175):986.

8. Gradishar WJ, Moran MS, Abraham J, Aſt R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Mar.;23 (Version 4.2023). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

9. Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485–1505. https://doi.org/10.1200/jco.20.03399

10. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–2284. https://doi.org/10.1093/annonc/mdt182

11. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13–21. https://doi.org/10.1200/jco.2014.57.0572

12. Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers (Basel). 2022 Apr 9;14(8):1898. https://doi.org/10.3390/cancers14081898

13. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-Analysis Confirms Achieving Pathological Complete Response Aſter Neoadjuvant Chemotherapy Predicts Favourable Prognosis for Breast Cancer Patients. Eur J Cancer. 2011;47(14):2084–2090. https://doi.org/10.1016/j.ejca.2011.06.014

14. Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, et al. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response Aſter Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018;210(6):1376–1385. https://doi.org/10.2214/ajr.17.18323

15. Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, et al. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) aſter neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res. 2019 Jan 31;21(1):19. https://doi.org/10.1186/s13058-018-1091-y

16. O’Donnell JPM, Gasior SA, Davey MG, O’Malley E, Lowery AJ, McGarry J, et al. The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: A systematic review and network meta-analysis. Eur J Radiol. 2022 Dec;157:110561. https://doi.org/10.1016/j.ejrad.2022.110561

17. Hong J, Rui W, Fei X, Chen X, Shen K. Association of tumor-infiltrating lymphocytes before and aſter neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. Cancer Med. 2021 Nov;10(22):7921–7933. https://doi.org/10.1002/cam4.4302

18. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015 Jun 1;75(11):2139–2145. https://doi.org/10.1158/0008-5472.can-15-0255

19. Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012 Oct;43(10):1688–1694. https://doi.org/10.1016/j.humpath.2011.12.013

20. Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med. 2015 Jun 4;13:180. https://doi.org/10.1186/s12967-015-0535-8

21. Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother. 2012 Feb;61(2):239–247. https://doi.org/10.1007/s00262-011-1148-6

22. Li C, Lu N, He Z, Tan Y, Liu Y, Chen Y, et al. A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg Oncol. 2022 Nov;29(12):7685–7693. https://doi.org/10.1245/s10434-022-12034-w

23. Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis. Clin Breast Cancer. 2017 Jul;17(4):245–255. https://doi.org/10.1016/j.clbc.2016.12.010

24. Cao K, Zhao B, Li XT, Li YL, Sun YS. Texture Analysis of Dynamic Contrast-Enhanced MRI in Evaluating Pathologic Complete Response (pCR) of Mass-Like Breast Cancer aſter Neoadjuvant Therapy. J Oncol. 2019 Dec 26;2019:4731532. https://doi.org/10.1155/2019/4731532

25. Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, Malyarenko D, et al. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2019 Jun;49(7):e101–e121. https://doi.org/10.1002/jmri.26518